CRISPR Therapeutics Announces $280 Million Registered Direct Offering
CRISPR Therapeutics(CRSP) Newsfilter·2024-02-13 21:30- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transfo ...